Mirum Pharmaceuticals (MIRM) Gross Margin (2023 - 2026)

Mirum Pharmaceuticals' Gross Margin history runs 4 years deep, the most recent figure standing at 81.98% for Q1 2026.

• In Q1 2026, Gross Margin rose 261.0% year-over-year to 81.98%; the TTM figure through Mar 2026 stood at 81.39% (up 428.0% YoY), while the FY2025 annual figure was 80.77%, up 501.0% from the prior year.
• Gross Margin was 81.98% for Q1 2026 at Mirum Pharmaceuticals, up from 81.02% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 84.24% in Q1 2023 to a low of 64.03% in Q4 2023.
• Historically, Gross Margin has averaged 78.14% across 4 years, with a median of 79.37% in 2025.
• Biggest YoY gain for Gross Margin was 1306 bps in 2024; the steepest drop was 1000 bps in 2024.
• A 4-year view of Gross Margin shows it stood at 64.03% in 2023, then gained by 20 bps to 77.09% in 2024, then increased by 5 bps to 81.02% in 2025, then climbed by 1 bps to 81.98% in 2026.
• The last three Gross Margin figures came in at 81.98% (Q1 2026), 81.02% (Q4 2025), and 80.8% (Q3 2025), per Business Quant data.